GSK to withdraw Blenrep ’s U.S. marketing authorization after FDA request

GSK PLC GSK, The pharmaceutical giant said the request comes after its Dreamm-3 Phase 3 study in patients with relapsed or refractory multiple myeloma didn’t meet its primary endpoint of progression-free survival. The company said patients treated with Blenrep therapy who have been already…#gskplc #gsk #plc #multiplemyeloma #sabineluik #program #michaelsusin #blenreptherapy #multiple #myeloma

Source: Reuters: Health - November 22, 2022 Category: Consumer Health News Source Type: news